ESMO: Novel Checkpoint Inhibitors From Merck And BMS Show Promise
Patients Progressing On PD-1/PD-L1s Need Options
This year's virtual ESMO saw noteworthy advances in esophageal and melanoma combination therapies, with a crop of new mechanisms also showcased. 
